Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013;18(4):e16-7.
doi: 10.1634/theoncologist.2012-0320. Epub 2013 Apr 10.

Geographic tongue induced by angiogenesis inhibitors

Thomas Hubiche, Bruno Valenza, Christine Chevreau, Jean-Christophe Fricain, Pascal Del Giudice, Vincent Sibaud
Comment

Geographic tongue induced by angiogenesis inhibitors

Thomas Hubiche et al. Oncologist. 2013.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

Figure 1.
Figure 1.
Typical geographic tongue induced by bevacizumab.
Figure 2.
Figure 2.
A, B: Fading of the lesions 3 weeks after bevacizumab injection.
Figure 3.
Figure 3.
(Sunitinib): Migratory well-demarcated areas with elevated yellowish hyperkeratotic borders.
Figure 4.
Figure 4.
(Sorafenib): Erythematous erosions, with loss of filiform papillae, surrounded by white circinate rims.
See this image and copyright information in PMC

Comment in

  • In reply.
    Rosen AC, Gavrilovic IT, Balagula Y, Ramaswamy V, Dickler MN, Dunkel IJ, Lacouture ME. Rosen AC, et al. Oncologist. 2013;18(4):e18. doi: 10.1634/theoncologist.2012-0421. Epub 2013 Apr 10. Oncologist. 2013. PMID: 23576479 Free PMC article.

Comment on

References

    1. Gavrilovic IT, Balagula Y, Rosen AC, et al. Characteristics of oral mucosal events related to bevacizumab treatment. The Oncologist. 2012;17:274–278. - PMC - PubMed
    1. Assimakopoulos D, Patrikakos G, Fotika C, et al. Benign migratory glossitis or geographic tongue: an enigmatic oral lesion. Am J Med. 2002;113:751–755. - PubMed
    1. Maharaj ASR, Saint-Gebiez M, Maldonado AE, et al. Vascular endothelial growth factor localization in the adult. Am J Pathol. 2006;168:639–648. - PMC - PubMed
    1. Zhou G, Hasina R, Wroblewski K, et al. inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis. Cancer Prev Res. 2010;3:1493–1502. - PMC - PubMed
    1. Boers-Doets CB, Epstein JB, Raber-Durlacher JE, et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. The Oncologist. 2012;17:135–144. - PMC - PubMed

Substances

LinkOut - more resources